AXGN
NASDAQAxogen Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$37.45+5.62 (+17.64%)
2026-01-202026-04-23
News · 26 weeks58-67%
2025-10-262026-04-19
Mix1790d
- Insider8(47%)
- Earnings2(12%)
- Other2(12%)
- SEC Filings2(12%)
- Analyst1(6%)
- Offering1(6%)
- Other1(6%)
Latest news
25 items- PRCVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsMINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical device industry, and I'm excited for him to join our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "His extensive experience leading high growth organizations, both as an executi
- PRAxogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the first quarter of 2026 on Tuesday, April 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Axogen Inc.SCHEDULE 13G/A - Axogen, Inc. (0000805928) (Subject)
- INSIDERSEC Form 4 filed by Devinney Erick Wayne4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Hartley Lindsey Marie4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERChief Marketing Officer Kemp Jens was granted 50,670 shares and covered exercise/tax liability with 18,366 shares, increasing direct ownership by 73% to 76,451 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERChief Innovation Officer Devinney Erick Wayne was granted 33,780 shares and covered exercise/tax liability with 21,978 shares, increasing direct ownership by 5% to 252,934 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDEREVP & General Counsel Began Marc A converted options into 11,250 shares, was granted 33,780 shares and covered exercise/tax liability with 13,180 shares, increasing direct ownership by 174% to 50,135 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERCFO Hartley Lindsey Marie was granted 17,453 shares and covered exercise/tax liability with 6,630 shares, increasing direct ownership by 24% to 55,276 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Dale Michael D4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERCFO Hartley Lindsey Marie covered exercise/tax liability with 6,704 shares and was granted 17,500 shares, increasing direct ownership by 32% to 44,453 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- SECSEC Form 10-K filed by Axogen Inc.10-K - Axogen, Inc. (0000805928) (Filer)
- SECAxogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- PRAxogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial ResultsALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial Results Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue. Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the fourth quarter of 2024, and down from 76.6% in the third quarter of 2025. Gross margin refl
- ANALYSTWells Fargo initiated coverage on AxoGen with a new price targetWells Fargo initiated coverage of AxoGen with a rating of Overweight and set a new price target of $40.00
- PRAxogen, Inc. to Participate in Multiple Upcoming Investor ConferencesALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Raymond James 47th Annual Institutional Investors ConferenceParticipation: Presentation and 1x1 investor meetingsDate/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ETWebcast Link: Raymond James/Axogen Presentation Leerink Global Healthcare ConferenceParticipation: Fireside Chat and 1x1 investor meetingsDate/Time: Fireside Chat Monday, March 9, 2026, 1:00 PM ETWebcast Link
- PRAxogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event
- SECAxogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- SECSEC Form 424B5 filed by Axogen Inc.424B5 - Axogen, Inc. (0000805928) (Filer)
- PRAxogen Announces Pricing of Upsized $124 Million Public Offering of Common StockALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and com
- SECSEC Form 424B5 filed by Axogen Inc.424B5 - Axogen, Inc. (0000805928) (Filer)
- PRAxogen Announces Proposed Public Offering of Common StockALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common stock. All of the shares to be sold in the proposed offering are to be sold by Axogen. There can be no assurance as to whether or when the offering may be comple
- SECSEC Form S-3ASR filed by Axogen Inc.S-3ASR - Axogen, Inc. (0000805928) (Filer)
- SECAxogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- PRAxogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, driven by solid performance across the product portfolio.Full-year 2025 revenue is expected to be approximately $225.2 million, which represents a 20.2% increase over the full-year of 2